Cost-effectiveness

While pathogen-inactivated blood components are more expensive to produce than non-treated blood components, the INTERCEPT™ Blood System offers many cost-saving opportunities for hospitals. To ensure that clinicians use the safest possible blood components, many countries have approved incremental reimbursement for pathogen-inactivated blood components.